North America Bacterial Vaginosis Drug Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Prescription Drugs and Over-the-Counter Drugs), Route of Administration (Oral, Topical, and Vaginal), Dosage Form (Creams, Gels, Pills, Solutions/Washes, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
The North America Bacterial Vaginosis Drug Market is projected to grow significantly, reaching an estimated US$ 1,688.3 million by 2031, up from US$ 942.6 million in 2024. This growth represents a compound annual growth rate (CAGR) of 8.5% from 2023 to 2031, driven by several key factors.
Executive Summary
The market for bacterial vaginosis (BV) drugs in North America is primarily segmented into three countries: the United States, Canada, and Mexico. The increasing prevalence of BV, heightened awareness regarding women's health issues, and the continuous development of innovative treatment options are all contributing to the market's expansion. In the United States, government initiatives are actively promoting awareness and education about BV, which further supports market growth. Additionally, improved healthcare access, rising disposable incomes, and a broader array of treatment options are propelling the market forward during the forecast period.
Market Segmentation
The North America Bacterial Vaginosis Drug Market can be segmented based on several criteria:
1. By Type: The market is divided into Prescription Drugs (Rx) and Over-the-Counter Drugs (OTC). Prescription drugs are expected to hold the largest market share in 2024, reflecting the reliance on medically supervised treatments for BV.
2. By Route of Administration: This market is categorized into Oral, Vaginal, and Topical routes. Oral administration is anticipated to dominate the market share in 2024, likely due to the convenience and effectiveness of oral medications.
3. By Dosage Form: The market is segmented into Pills, Creams, Gels, Solutions or Washes, and Others. Pills are projected to hold the largest share in 2024, as they are a common and preferred form of medication for many patients.
4. By Distribution Channel: The market is divided into Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Hospital Pharmacies are expected to capture the largest share in 2024, reflecting the critical role of healthcare facilities in providing treatment for BV.
Market Outlook
Bacterial vaginosis is a prevalent condition among women of childbearing age, often resulting from an imbalance in the normal bacterial flora of the vagina. This condition is characterized by a decrease in Lactobacillus species and an increase in various anaerobic bacteria, leading to symptoms such as abnormal vaginal discharge, odor, and itching. Factors such as unprotected sexual intercourse and frequent douching can exacerbate the risk of developing BV.
According to recent studies, the global prevalence of BV ranges from 23% to 29%, with rates in pregnant women reaching as high as 49%. In the United States alone, approximately one-third of adult women, or around 22 million, are affected by BV annually, with 10 million seeking medical attention for related symptoms. The condition poses significant health risks, including preterm labor, miscarriage, and increased susceptibility to sexually transmitted infections (STIs), which drives women to seek effective pharmaceutical interventions.
The high recurrence rate of BV necessitates the development of comprehensive treatment regimens aimed at preventing relapses. As healthcare access improves, particularly in emerging markets, more women are seeking treatment for BV, further stimulating market growth.
Country Insights
The North American market is primarily dominated by the United States, which is experiencing robust growth in the bacterial vaginosis drug sector. The increasing incidence of BV, coupled with rising awareness of women's health issues and the introduction of innovative treatments, is fueling this growth. BV is one of the most common vaginal infections among women, particularly those of reproductive age.
The primary therapeutic options for treating BV include antibiotics approved by the U.S. Food and Drug Administration (FDA), such as metronidazole and clindamycin. Metronidazole is often the first-line treatment and is available in both oral and topical forms, while clindamycin is also offered in similar formulations. Emerging treatments, including probiotics and phage therapy, are being developed to restore the natural vaginal flora and reduce recurrence rates.
Competitive Landscape
Key players in the Bacterial Vaginosis Drug Market include Bayer AG, Pfizer Inc., Viatris Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, Lupin Ltd, Glenmark Pharmaceuticals Ltd, Organon & Co., Starpharma Holdings Limited, and Duchesnay Inc. These companies are employing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase market share.
In summary, the North America Bacterial Vaginosis Drug Market is poised for significant growth, driven by increasing prevalence, awareness, and the development of new treatment options. As healthcare access continues to improve, the demand for effective BV treatments is expected to rise, creating opportunities for pharmaceutical companies in this sector.
Executive Summary
The market for bacterial vaginosis (BV) drugs in North America is primarily segmented into three countries: the United States, Canada, and Mexico. The increasing prevalence of BV, heightened awareness regarding women's health issues, and the continuous development of innovative treatment options are all contributing to the market's expansion. In the United States, government initiatives are actively promoting awareness and education about BV, which further supports market growth. Additionally, improved healthcare access, rising disposable incomes, and a broader array of treatment options are propelling the market forward during the forecast period.
Market Segmentation
The North America Bacterial Vaginosis Drug Market can be segmented based on several criteria:
1. By Type: The market is divided into Prescription Drugs (Rx) and Over-the-Counter Drugs (OTC). Prescription drugs are expected to hold the largest market share in 2024, reflecting the reliance on medically supervised treatments for BV.
2. By Route of Administration: This market is categorized into Oral, Vaginal, and Topical routes. Oral administration is anticipated to dominate the market share in 2024, likely due to the convenience and effectiveness of oral medications.
3. By Dosage Form: The market is segmented into Pills, Creams, Gels, Solutions or Washes, and Others. Pills are projected to hold the largest share in 2024, as they are a common and preferred form of medication for many patients.
4. By Distribution Channel: The market is divided into Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Hospital Pharmacies are expected to capture the largest share in 2024, reflecting the critical role of healthcare facilities in providing treatment for BV.
Market Outlook
Bacterial vaginosis is a prevalent condition among women of childbearing age, often resulting from an imbalance in the normal bacterial flora of the vagina. This condition is characterized by a decrease in Lactobacillus species and an increase in various anaerobic bacteria, leading to symptoms such as abnormal vaginal discharge, odor, and itching. Factors such as unprotected sexual intercourse and frequent douching can exacerbate the risk of developing BV.
According to recent studies, the global prevalence of BV ranges from 23% to 29%, with rates in pregnant women reaching as high as 49%. In the United States alone, approximately one-third of adult women, or around 22 million, are affected by BV annually, with 10 million seeking medical attention for related symptoms. The condition poses significant health risks, including preterm labor, miscarriage, and increased susceptibility to sexually transmitted infections (STIs), which drives women to seek effective pharmaceutical interventions.
The high recurrence rate of BV necessitates the development of comprehensive treatment regimens aimed at preventing relapses. As healthcare access improves, particularly in emerging markets, more women are seeking treatment for BV, further stimulating market growth.
Country Insights
The North American market is primarily dominated by the United States, which is experiencing robust growth in the bacterial vaginosis drug sector. The increasing incidence of BV, coupled with rising awareness of women's health issues and the introduction of innovative treatments, is fueling this growth. BV is one of the most common vaginal infections among women, particularly those of reproductive age.
The primary therapeutic options for treating BV include antibiotics approved by the U.S. Food and Drug Administration (FDA), such as metronidazole and clindamycin. Metronidazole is often the first-line treatment and is available in both oral and topical forms, while clindamycin is also offered in similar formulations. Emerging treatments, including probiotics and phage therapy, are being developed to restore the natural vaginal flora and reduce recurrence rates.
Competitive Landscape
Key players in the Bacterial Vaginosis Drug Market include Bayer AG, Pfizer Inc., Viatris Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, Lupin Ltd, Glenmark Pharmaceuticals Ltd, Organon & Co., Starpharma Holdings Limited, and Duchesnay Inc. These companies are employing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase market share.
In summary, the North America Bacterial Vaginosis Drug Market is poised for significant growth, driven by increasing prevalence, awareness, and the development of new treatment options. As healthcare access continues to improve, the demand for effective BV treatments is expected to rise, creating opportunities for pharmaceutical companies in this sector.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BACTERIAL VAGINOSIS DRUG MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Incidence Rate: Bacterial Vaginosis
5. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BACTERIAL VAGINOSIS DRUG MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Bacterial Vaginosis Drug Market Revenue (US$ Million), 2024 - 2031
6.2 North America Bacterial Vaginosis Drug Market Forecast and Analysis
7. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs (Rx)
7.1.1 Overview
7.1.2 Prescription Drugs (Rx): North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Over-the-counter Drugs (OTC)
7.2.1 Overview
7.2.2 Over-the-counter Drugs (OTC): North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
8.1 Oral
8.1.1 Overview
8.1.2 Oral: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Vaginal
8.2.1 Overview
8.2.2 Vaginal: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Topical
8.3.1 Overview
8.3.2 Topical: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET REVENUE ANALYSIS - BY DOSAGE FORM
9.1 Pills
9.1.1 Overview
9.1.2 Pills: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Creams
9.2.1 Overview
9.2.2 Creams: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Gel
9.3.1 Overview
9.3.2 Gel: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Solution or Washes
9.4.1 Overview
9.4.2 Solution or Washes: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.1.1 Overview
10.1.2 Hospital Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Online Pharmacies
10.2.1 Overview
10.2.2 Online Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Retail Pharmacies
10.3.1 Overview
10.3.2 Retail Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET - COUNTRY ANALYSIS
11.1 North America
11.1.1 North America Bacterial Vaginosis Drug Market Revenue and Forecast and Analysis - by Country
11.1.1.1 North America Bacterial Vaginosis Drug Market Revenue and Forecast and Analysis - by Country
11.1.2.2 United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 United States: North America Bacterial Vaginosis Drug Market Share - by Type
11.1.2.2.2 United States: North America Bacterial Vaginosis Drug Market Share - by Route Of Administration
11.1.2.2.3 United States: North America Bacterial Vaginosis Drug Market Share - by Dosage Form
11.1.2.2.4 United States: North America Bacterial Vaginosis Drug Market Share - by Distribution Channel
11.2.3.3 Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Canada: North America Bacterial Vaginosis Drug Market Share - by Type
11.2.3.3.2 Canada: North America Bacterial Vaginosis Drug Market Share - by Route Of Administration
11.2.3.3.3 Canada: North America Bacterial Vaginosis Drug Market Share - by Dosage Form
11.2.3.3.4 Canada: North America Bacterial Vaginosis Drug Market Share - by Distribution Channel
11.3.4.4 Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Mexico: North America Bacterial Vaginosis Drug Market Share - by Type
11.3.4.4.2 Mexico: North America Bacterial Vaginosis Drug Market Share - by Route Of Administration
11.3.4.4.3 Mexico: North America Bacterial Vaginosis Drug Market Share - by Dosage Form
11.3.4.4.4 Mexico: North America Bacterial Vaginosis Drug Market Share - by Distribution Channel
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Bayer AG
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Viatris Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Sanofi SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Sun Pharmaceutical Industries Ltd
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Lupin Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Glenmark Pharmaceuticals Ltd
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Organon & Co
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Starpharma Holdings Limited
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Duchesnay Inc., Canada
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. BACTERIAL VAGINOSIS DRUG MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Incidence Rate: Bacterial Vaginosis
5. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. BACTERIAL VAGINOSIS DRUG MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Bacterial Vaginosis Drug Market Revenue (US$ Million), 2024 - 2031
6.2 North America Bacterial Vaginosis Drug Market Forecast and Analysis
7. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs (Rx)
7.1.1 Overview
7.1.2 Prescription Drugs (Rx): North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Over-the-counter Drugs (OTC)
7.2.1 Overview
7.2.2 Over-the-counter Drugs (OTC): North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
8.1 Oral
8.1.1 Overview
8.1.2 Oral: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Vaginal
8.2.1 Overview
8.2.2 Vaginal: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Topical
8.3.1 Overview
8.3.2 Topical: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET REVENUE ANALYSIS - BY DOSAGE FORM
9.1 Pills
9.1.1 Overview
9.1.2 Pills: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Creams
9.2.1 Overview
9.2.2 Creams: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Gel
9.3.1 Overview
9.3.2 Gel: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Solution or Washes
9.4.1 Overview
9.4.2 Solution or Washes: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.1.1 Overview
10.1.2 Hospital Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Online Pharmacies
10.2.1 Overview
10.2.2 Online Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Retail Pharmacies
10.3.1 Overview
10.3.2 Retail Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. NORTH AMERICA BACTERIAL VAGINOSIS DRUG MARKET - COUNTRY ANALYSIS
11.1 North America
11.1.1 North America Bacterial Vaginosis Drug Market Revenue and Forecast and Analysis - by Country
11.1.1.1 North America Bacterial Vaginosis Drug Market Revenue and Forecast and Analysis - by Country
11.1.2.2 United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 United States: North America Bacterial Vaginosis Drug Market Share - by Type
11.1.2.2.2 United States: North America Bacterial Vaginosis Drug Market Share - by Route Of Administration
11.1.2.2.3 United States: North America Bacterial Vaginosis Drug Market Share - by Dosage Form
11.1.2.2.4 United States: North America Bacterial Vaginosis Drug Market Share - by Distribution Channel
11.2.3.3 Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Canada: North America Bacterial Vaginosis Drug Market Share - by Type
11.2.3.3.2 Canada: North America Bacterial Vaginosis Drug Market Share - by Route Of Administration
11.2.3.3.3 Canada: North America Bacterial Vaginosis Drug Market Share - by Dosage Form
11.2.3.3.4 Canada: North America Bacterial Vaginosis Drug Market Share - by Distribution Channel
11.3.4.4 Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Mexico: North America Bacterial Vaginosis Drug Market Share - by Type
11.3.4.4.2 Mexico: North America Bacterial Vaginosis Drug Market Share - by Route Of Administration
11.3.4.4.3 Mexico: North America Bacterial Vaginosis Drug Market Share - by Dosage Form
11.3.4.4.4 Mexico: North America Bacterial Vaginosis Drug Market Share - by Distribution Channel
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 Bayer AG
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Viatris Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Sanofi SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Sun Pharmaceutical Industries Ltd
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Lupin Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Glenmark Pharmaceuticals Ltd
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Organon & Co
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Starpharma Holdings Limited
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Duchesnay Inc., Canada
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. North America Bacterial Vaginosis Drug Market Segmentation
Table 3. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 6. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Dosage Form
Table 7. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 10. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 11. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Dosage Form
Table 12. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 14. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 15. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Dosage Form
Table 16. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 18. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 19. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Dosage Form
Table 20. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Heat Map Analysis by Key Players
Table 1. North America Bacterial Vaginosis Drug Market Segmentation
Table 3. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 6. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Dosage Form
Table 7. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 10. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 11. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Dosage Form
Table 12. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 14. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 15. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Dosage Form
Table 16. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 18. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 19. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Dosage Form
Table 20. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. North America Bacterial Vaginosis Drug Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. North America Bacterial Vaginosis Drug Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Bacterial Vaginosis Drug Market Revenue (US$ Million), 2024 - 2031
Figure 7. North America Bacterial Vaginosis Drug Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs (Rx): North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Over-the-counter Drugs (OTC): North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Bacterial Vaginosis Drug Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 11. Oral: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Vaginal: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Topical: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. North America Bacterial Vaginosis Drug Market Share (%) - by Dosage Form, 2024 and 2031
Figure 15. Pills: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Creams: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Gel: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Solution or Washes: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Others: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. North America Bacterial Vaginosis Drug Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 21. Hospital Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Online Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Retail Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. North America Bacterial Vaginosis Drug Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Company Positioning & Concentration
Figure 1. North America Bacterial Vaginosis Drug Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. North America Bacterial Vaginosis Drug Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Bacterial Vaginosis Drug Market Revenue (US$ Million), 2024 - 2031
Figure 7. North America Bacterial Vaginosis Drug Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs (Rx): North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Over-the-counter Drugs (OTC): North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Bacterial Vaginosis Drug Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 11. Oral: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Vaginal: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Topical: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. North America Bacterial Vaginosis Drug Market Share (%) - by Dosage Form, 2024 and 2031
Figure 15. Pills: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Creams: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Gel: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Solution or Washes: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Others: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. North America Bacterial Vaginosis Drug Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 21. Hospital Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Online Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Retail Pharmacies: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. North America Bacterial Vaginosis Drug Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 25. United States: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Canada: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Mexico: North America Bacterial Vaginosis Drug Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Company Positioning & Concentration
